Transaction also includes $30 million in milestones and allows Bayer the use of research platform.

Bayer HealthCare is acquiring Maxygen’s hemophilia program for $90 million upfront. Maxygen also has the potential to receive $30 million in milestone fees based on the advancement of this preclinical asset.


This agreement includes a license to use Maxygen’s MolecularBreeding™ technology for exploiting gene targets. Bayer HealthCare will also gain a recombinant factor VIIa protein known as MAXY-VII. Phase I testing of the candidate is expected to begin in the third quarter.


MAXY-VII is a factor VIIa clotting factor that may offer an improved dosing regimen and safety profile, the companies explain. Bayer already offers a recombinant factor VIII product, Kogenate®.


“The agreement fits into our growth strategy for our specialty pharmaceutical business and builds on our expertise in the commercialization and manufacturing of protein therapeutics,” remarks Gunnar Riemann, Ph.D., member of the executive committee of Bayer HealthCare.


With regards to the MolecularBreeding platform, Bayer has the exclusive right to use the technology for 30 specified gene targets in various areas of intered. The firm also obtained a nonexclusive license to use the instrument for a broad set of genes in its specialty pharmaceutical business.

Previous articleProtein that Can Predict Prostate Cancer Metastasis Identified
Next articleNEW INITIATIVE FOR MAPPING ALL CELL TYPES DERIVED FROM HUMAN EMBRYONIC STEM CELLS